Skip to content

Regulatory Considerations Expert Group reviews draft FDA Guidance

Date: June 19, 2023

The ACDM Regulatory Considerations Expert Group have reviewed and submitted comments on the recent draft FDA Guidance: Electronic Systems, Electronic Records, and Electronic Signatures in Clinical Investigations Questions and Answers.

The guidance provides an overall overview about the most relevant key points to consider on the use of electronic systems, electronic records and electronic signatures in clinical investigations. It also provides recommendations regarding the requirements, under 21 CFR part 11, under which FDA considers electronic systems, electronic records, and electronic signatures to be trustworthy, reliable, and generally equivalent to paper records and handwritten signatures executed on paper.

This guidance has been open for public consultation and the Regulatory Considerations Expert Group have provided feedback to the FDA on some points that may need further clarity, on behalf of the ACDM. The final guidance is expected to be released once the FDA have reviewed and agreed on implementation feedback received for the whole international clinical trials community.

The ACDM Regulatory Considerations Expert Group looks at providing guidance information on a number of areas surrounding regulations. If you are interested in joining, find out more here: https://acdmglobal.org/regulatory-considerations-dmeg/

 


 

Explore More News

AI model trained on de-identified data from 57 million people

Researchers at UCL have trained an AI model using de-identified data from 57 million . . .

Read More

ACDM Regulatory Considerations DMEG Update: ICH E6 (R3) GCP Final Publication Released

The final publication of ICH E6 (R3) Good Clinical Practice (GCP) General Principles and . . .

Read More

ICH E6(R3) Guideline reaches Step 4 of the ICH Process

ICH E6(R3) reaches Step 4 of the ICH Process on 6th January 2025. The guideline . . .

Read More

U.S. Food & Drug Administration: Draft Guidance for Industry and Other Interested Parties

The U.S. Food and Drug Administration has issued its first guidance on the use of . . .

Read More

ACDM DMEG News: Regulatory Updates and Forthcoming Challenges for 2025

As 2024 draws to a close, the Regulatory Considerations Data Management Expert Group . . .

Read More

Audit Trail Review DMEG Update – New Guide

The Audit Trail Review (ATR) DMEG has been hard at work putting the finishing touches on a . . .

Read More

Risk Based Quality Management DMEG Update – Recent Discussions

This year our focus has switched away from generalised RBQM to applying risk-based . . .

Read More

Regulatory Considerations DMEG Update – September 2024

The Regulatory Considerations DMEG are waiting for the release of ICH GCP E6 (R3) Annex 1 . . .

Read More

Digital Data Flow (DDF) integration through the lens of electronic Patient-Reported Outcomes (ePRO)

This article has been submitted by Leeni Joshua of ICON plc Introduction: Digital Data . . .

Read More

Guidance for Industry: Conducting Clinical Trials With Decentralized Elements

The Conducting Clinical Trials With Decentralized Elements final guidance has now been . . .

Read More

Welcome FGK Clinical Research as a new corporate member

The ACDM: Association for Clinical Data Management is delighted to welcome FGK Clinical . . .

Read More

Welcome LINK Medical as a new corporate member

The ACDM: Association for Clinical Data Management is delighted to welcome LINK Medical as . . .

Read More